March 11 (Reuters) - Acadia Pharmaceuticals said on Monday its experimental drug to treat negative symptoms of schizophrenia failed to meet the main goal in a late-stage study. (Reporting by Mariam Sunny in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.25 USD | +1.47% | +3.23% | -44.91% |
Apr. 30 | UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating | MT |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.91% | 2.85B | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+47.07% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study